Pfizer, Astellas speed up Phase III trials of Xtandi in hormone-sensitive prostate cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) amended the Phase III ARCHES and EMBARK trials of Xtandi enzalutamide to treat hormone-sensitive prostate cancer and now expect to complete both trials sooner than previously guided. The partners moved up ARCHES's expected completion date to late 2018 from April 2020 previously, and EMBARK's expected completion date to mid-2020 from March 2021.

The companies said changes to ARCHES's protocol include revisions to the planned analyses of the primary and secondary endpoints. The trial completed enrollment this year. ARCHES’ primary endpoint is radiographic progression-free survival (PFS)...